Tag: vaccine contract manufacturing industry forecast

  • Jynneos Market Forecast To 2030: Starting From $ Billion In 2026

    Jynneos Market Forecast To 2030: Starting From $ Billion In 2026

    Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

    Jynneos Market Expansion Outlook: What Revenue Opportunities Are Ahead?

    The expansion observed during the historical timeframe was primarily due to worldwide initiatives aimed at eradicating smallpox, preceding monkeypox outbreaks, the creation of more secure vaccinia platforms, governmental readiness strategies, and public health immunization campaigns.

    The expansion observed throughout the forecast period is due to factors such as escalating zoonotic disease threats, the enlargement of national vaccine supplies, increased financial support for biodefense, enhancements in global surveillance networks, and wider adult vaccination campaigns. Significant developments anticipated during this period encompass a stronger emphasis on preventing newly emerging infectious diseases, the proliferation of non-replicating vaccine technologies, the scaling up of governmental immunization programs, a surge in the strategic stockpiling of vaccines, and heightened public awareness concerning zoonotic illnesses.

    Get A Free Sample Report With In-Depth Market Insights:

    https://thebusinessresearchcompany.com/sample_request?id=63212499&type=smp&name=Jynneos%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

    Jynneos Market Growth Backed By Core Demand Fundamentals

    The increasing incidence of monkeypox cases is anticipated to drive the Jynneos market’s expansion. Monkeypox is a viral illness caused by the monkeypox virus, a member of the orthopoxvirus family. Cases of monkeypox arise due to heightened global travel and greater interaction between wildlife and humans, which facilitates the rapid transmission of infectious agents and transforms isolated outbreaks. Jynneos offers benefits for monkeypox cases as it effectively prevents the virus in at-risk individuals and provides a safer option for those with weakened immune systems compared to traditional smallpox vaccines. For example, in September 2024, the European Centre for Disease Prevention and Control, a Europe-based government agency, reported that from January 2022 to July 2024, over 100,000 confirmed cases of pox attributed to monkeypox virus (MPXV) clade I and clade II, along with over 200 deaths, were documented by more than 120 countries globally. Consequently, the rising number of monkeypox cases is stimulating the growth of the Jynneos market.

    Jynneos Market Driver: Development Of Combined Vaccines To Enhance Public Health Preparedness

    The principal company operating in the Jynneos market is concentrating on creating combined vaccines designed to address multiple disease targets simultaneously. Combined vaccines are immunizations that provide protection against several diseases with a single injection, thereby reducing the total number of shots required for full immunity. As an illustration, in August 2024, Bavarian Nordic A/S, a Denmark-based biotechnology company, announced that Singapore’s Health Sciences Authority (HSA) had granted approval for JYNNEOS (MVA-BN) for the prevention of smallpox and pox in adults aged 18 and older who are considered at high risk for these infections. JYNNEOS (MVA-BN) is a non-replicating vaccine formulated to offer a safer alternative for individuals, including those with compromised immune systems. Its development aimed to improve public health readiness and confront nascent infectious diseases.

    Jynneos Market Segment Analysis And Revenue Potential

    The jynneos market covered in this report is segmented –

    1) By Indication: Prevention of Monkeypox, Prevention of Smallpox

    2) By Formulation: Injectable Formulation, Lyophilized Powder for Reconstitution

    3) By Patient Demographics: Adult Patients, Pediatric Patients, High-Risk Populations

    4) By Distribution channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

    5) By End User: Hospitals, Specialty Clinics, Public Health Organizations, Home Healthcare Providers

    Jynneos Market Key Players Shaping Industry Direction

    Major companies operating in the jynneos market are Bavarian Nordic A/S

    View The Full Jynneos Market Report:

    https://thebusinessresearchcompany.com/report/jynneos-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

    Jynneos Market Global Footprint: Which Region Leads The Market?

    North America was the largest region in the jynneos market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the jynneos market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Reach Out To Our Team:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Jynneos Market Expansion Is Reshaping Competitive Dynamics Across The Industry

    Jynneos Market Expansion Is Reshaping Competitive Dynamics Across The Industry

    Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

    Jynneos Market CAGR Analysis And Future Market Development

    The expansion observed during the historical timeframe is linked to worldwide campaigns aimed at wiping out smallpox, previous occurrences of monkeypox outbreaks, the creation of more secure vaccinia-based systems, government-led readiness measures, and public health vaccination programs.

    Growth during the forecast period is expected to be driven by heightened risks from zoonotic diseases, the enlargement of national vaccine stockpiles, increased financial support for biodefense initiatives, enhanced worldwide monitoring networks, and the broadening of adult vaccination campaigns. Key developments shaping this period encompass a greater emphasis on preventing newly emerging infectious diseases, wider adoption of non-replicating vaccine platforms, an expansion of publicly funded immunization efforts, a surge in the strategic reserve of critical vaccines, and growing public understanding of illnesses transmitted from animals to humans.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20118&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

    Jynneos Market Demand Drivers: What Is Fueling Industry Growth?

    The growing number of monkeypox infections is anticipated to propel the Jynneos market forward. Monkeypox is a viral illness triggered by the monkeypox virus, a member of the orthopoxvirus family. Cases of monkeypox are on the rise due to increased international travel and heightened contact between wildlife and humans, which allows infectious agents to spread quickly and turn localized outbreaks into larger events. Jynneos proves valuable for monkeypox cases by effectively preventing the virus in high-risk individuals and providing a safer option for those with compromised immune systems when compared to conventional smallpox vaccines. For example, as reported in September 2024 by the European Centre for Disease Prevention and Control—a government agency based in Europe—more than 100,000 confirmed cases of pox caused by monkeypox virus (MPXV) clades I and II, including over 200 deaths, were documented across over 120 countries worldwide between January 2022 and July 2024. Consequently, the surge in monkeypox cases is fueling expansion in the Jynneos market.

    Jynneos Market Driver: Development Of Combined Vaccines To Enhance Public Health Preparedness

    Major players in the Jynneos market are concentrating on creating combined vaccines aimed at tackling multiple diseases simultaneously. Combined vaccines are immunizations that offer protection against several illnesses with a single shot, thereby minimizing the number of injections needed for complete immunization. In August 2024, for instance, Bavarian Nordic A/S, a biotechnology firm headquartered in Denmark, announced that Singapore’s Health Sciences Authority (HSA) had granted approval for JYNNEOS (MVA-BN) as a preventive measure against smallpox and pox in adults aged 18 and older deemed at high risk for these infections. JYNNEOS (MVA-BN) is a non-replicating vaccine crafted to provide a safer option for various individuals, including those who are immunocompromised. Its development was aimed at improving public health readiness and addressing new infectious disease threats.

    Jynneos Market Categorization By Product Type And Application

    The jynneos market covered in this report is segmented –

    1) By Indication: Prevention of Monkeypox, Prevention of Smallpox

    2) By Formulation: Injectable Formulation, Lyophilized Powder for Reconstitution

    3) By Patient Demographics: Adult Patients, Pediatric Patients, High-Risk Populations

    4) By Distribution channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

    5) By End User: Hospitals, Specialty Clinics, Public Health Organizations, Home Healthcare Providers

    Jynneos Market Company Landscape And Strategic Competition

    Major companies operating in the jynneos market are Bavarian Nordic A/S

    Access The Complete Jynneos Market Report:

    https://www.thebusinessresearchcompany.com/report/jynneos-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

    Jynneos Market Regional Outlook: Where Are The Largest Opportunities Located?

    North America was the largest region in the jynneos market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the jynneos market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Vaccine Contract Manufacturing Market Size Projected To Increase From $4.27 Billion To $6.46 Billion During The Forecast Period

    Vaccine Contract Manufacturing Market Size Projected To Increase From $4.27 Billion To $6.46 Billion During The Forecast Period

    Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

    Vaccine Contract Manufacturing Market Expected To Reach $6.46 Billion By 2030 At 10.9% CAGR

    The market for vaccine contract manufacturing experienced robust expansion recently. Projections indicate a rise from $3.88 billion in 2025 to $4.27 billion in 2026, reflecting a compound annual growth rate of 10.0%. This upward trajectory during the past period is largely due to the broader scope of worldwide vaccination initiatives, the escalating intricacy involved in manufacturing vaccines, the increasing dependence on expert contract manufacturing firms, the proliferation of collaborative efforts between public and private sectors for vaccine development, and the establishment of significant vaccine production infrastructure.

    Regarding the vaccine contract manufacturing sector, a significant increase in its market value is anticipated over the upcoming years, projected to reach $6.46 billion by the year 2030, demonstrating a compound annual growth rate of 10.9%. This upward trajectory during the projected timeframe is fueled by several key factors, including the escalating need for swift vaccine production scaling, augmented investment flowing into mRNA and innovative vaccine technologies, the broadening of commercial-scale manufacturing operations, a heightened emphasis on nations achieving their own vaccine production independence, and the integration of sophisticated bioprocessing techniques. Furthermore, prominent developments expected within this period encompass a greater tendency for vaccine production to be contracted out, a surge in the requirement for adaptable manufacturing capacities, extensions in the services offered for filling and finishing vaccines, a stronger concentration on manufacturing processes that adhere to regulatory standards, and a more widespread adoption of disposable bioprocessing equipment.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12216&type=smp

    Vaccine Contract Manufacturing Market Industry Drivers: What Is Driving Revenue Growth?

    The increasing prevalence of infectious diseases globally is anticipated to fuel the expansion of the vaccine contract manufacturing sector. Infectious diseases are conditions caused by disease-causing organisms including bacteria, viruses, fungi, or parasites, and their outbreaks, such as those involving influenza, measles, or novel viruses, necessitate a rapid increase in vaccine production to curb further transmission. Contract manufacturers possess the capability to swiftly enhance their output in reaction to these public health emergencies. Illustratively, data from the World Health Organization, a global health agency headquartered in Switzerland, indicated that in October 2024, roughly 8.2 million individuals received new tuberculosis diagnoses in 2023, an increase from approximately 7.5 million in 2022, positioning tuberculosis as the foremost fatal infectious disease, underscoring how the escalating global incidence of infectious diseases is a primary driver for the vaccine contract manufacturing market’s growth.

    Vaccine Contract Manufacturing Market Segment Landscape And Growth Potential

    The vaccine contract manufacturing market covered in this report is segmented –

    1) By Service Type: Fill-Finish, Bulk Product

    2) By Vaccine Type: Inactivated Vaccines, Live-Attenuated Vaccines, RNA (Ribonucleic Acid) Vaccines, Subunit Vaccines, Toxoid-Based Vaccines

    3) By Process: Downstream, Upstream

    4) By Scale Of Operation: Preclinical, Clinical, Commercial

    5) By End-Use: Human Use, Veterinary

    Subsegments:

    1) By Fill-Finish: Aseptic Fill-Finish, Lyophilization, Vial Filling, Syringe Filling

    2) By Bulk Product: Cell Culture, Microbial Fermentation, Antigen Production, Buffer Preparation

    #Vaccine Contract Manufacturing Market Growth Trends: What Is Influencing The Future Outlook?

    Leading entities within the vaccine contract manufacturing sector are prioritizing the inauguration of new production facilities to solidify their market standing. The establishment of these vaccine contract manufacturing sites signifies the creation of dedicated operational bases for producing vaccines under contract. As an illustration, WuXi Vaccines, a Chinese contract development and manufacturing organization renowned for its vaccine expertise, inaugurated its inaugural independent vaccine CDMO facility in Suzhou, China, in September 2023. This strategic expansion significantly boosts the company’s capacity for both the manufacturing of the core vaccine components and the final drug product. Consequently, WuXi Vaccines now provides an all-encompassing suite of services that span various vaccine types, encompassing process refinement, drug product formulation, and the manufacturing of clinical-stage drug substances alongside sterile drug products in small to medium volumes. This newly commissioned independent facility amplifies WuXi Vaccines’ potential to participate in vaccine creation and production, thereby assuming a crucial role in propelling global health advancements.

    Vaccine Contract Manufacturing Market Competitive Landscape: Who Are The Leading Companies?

    Major companies operating in the vaccine contract manufacturing market are Pfizer Inc, Johnson & Johnson, AbbVie Inc., Sanofi, GlaxoSmithKline, Merck KGaA, Moderna, BioNTech, GSK Vaccines, AstraZeneca PLC, Ajinomoto Co. Inc., Lonza Group AG, Catalent Inc., Charles River Laboratories International Inc., Serum Institute of India Pvt. Ltd, Samsung Biologics, WuXi Biologics, Novavax, Sinovac Biotech, Emergent BioSolutions Inc., Bio Farma, Hualan Biological Engineering, BioMARC, Bavarian Nordic A/S, AGC Biologics, IDT Biologika GmbH, Bharat Biotech, Goodwin Biotechnology Inc., Biofabri S.L

    Access The Complete Vaccine Contract Manufacturing Market Report:

    https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

    Vaccine Contract Manufacturing Market Regional Distribution: Which Areas Drive Market Expansion?

    North Americawas the largest region in the vaccine contract manufacturing market in 2025. Asia-Pacificis expected to be the fastest-growing region in the vaccine contract manufacturing market report forecast period. The regions covered in the vaccine contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Jynneos  Market Industry Outlook 2026–2030 Highlighting Growth Momentum And Market Trends

    Jynneos Market Industry Outlook 2026–2030 Highlighting Growth Momentum And Market Trends

    The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

    What Market Value Expansion Is Expected For The Jynneos Market Over The Forecast Period?

    The expansion seen historically was primarily due to global campaigns aimed at eradicating smallpox, previous instances of monkeypox outbreaks, the creation of more secure vaccinia platforms, government-led preparedness schemes, and general public health vaccination drives.

    The expansion anticipated during the forecast period is primarily driven by escalating risks associated with zoonotic diseases, the enlargement of national vaccine stockpiles, increased financial support for biodefense, enhanced global surveillance networks, and the implementation of more extensive adult vaccination programs. Furthermore, significant trends observed in the same forecast period involve a heightened emphasis on the prevention of emerging infectious diseases, the proliferation of non-replicating vaccine technologies, an expansion in government-led immunization initiatives, the increased stockpiling of strategic vaccines, and a growing public awareness of zoonotic illnesses.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20118&type=smp

    Which Significant Factors Are Encouraging Growth In The Jynneos Market?

    The jynneos market is projected to grow due to the increasing occurrence of monkeypox cases. Monkeypox, a viral illness caused by the monkeypox virus belonging to the orthopoxvirus family, sees a rise in cases attributed to increased global travel and more significant human-wildlife interactions, which facilitate the rapid spread of infectious agents beyond isolated outbreaks. Jynneos is effective against monkeypox as it provides robust viral prevention for at-risk individuals and is considered safer for those with weakened immune systems compared to traditional smallpox vaccines. For example, in September 2024, the European Centre for Disease Prevention and Control, a Europe-based government agency, reported over 100,000 confirmed cases of pox due to monkeypox virus (MPXV) clade I and clade II, including more than 200 deaths, across over 120 countries globally between January 2022 and July 2024. This increase in monkeypox cases is therefore a primary factor driving the expansion of the Jynneos market.

    Jynneos Market Driver: Development Of Combined Vaccines To Enhance Public Health Preparedness

    Key companies within the jynneos market are concentrating on developing combined vaccines to simultaneously target multiple diseases. Combined vaccines are immunizations that offer protection against several illnesses with a single injection, thereby reducing the number of shots needed for complete immunization. For instance, in August 2024, Bavarian Nordic A/S, a Denmark-based biotechnology company, announced that Singapore’s Health Sciences Authority (HSA) had approved JYNNEOS (MVA-BN) for preventing smallpox and pox in adults aged 18 and older who are at high risk for these infections. JYNNEOS (MVA-BN) is a non-replicating vaccine specifically designed to be a safer alternative for individuals, including those who are immunocompromised. Its development aims to bolster public health preparedness and address emerging infectious diseases effectively.

    What Segment Categories Are Evaluated In The Jynneos Market Study?

    The jynneos market covered in this report is segmented –

    1) By Indication: Prevention of Monkeypox, Prevention of Smallpox

    2) By Formulation: Injectable Formulation, Lyophilized Powder for Reconstitution

    3) By Patient Demographics: Adult Patients, Pediatric Patients, High-Risk Populations

    4) By Distribution channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

    5) By End User: Hospitals, Specialty Clinics, Public Health Organizations, Home Healthcare Providers

    Who Are The Key Market Participants In The Jynneos Market?

    Major companies operating in the jynneos market are Bavarian Nordic A/S

    Access The Complete Jynneos Market Report:

    https://www.thebusinessresearchcompany.com/report/jynneos-global-market-report

    Which Region Has The Strongest Presence In The Jynneos Market?

    North America was the largest region in the jynneos market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the jynneos market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Jynneos Market Forecast 2026–2030 Highlighting Expansion Across Industries

    Jynneos Market Forecast 2026–2030 Highlighting Expansion Across Industries

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Is The Forecasted Market Size Trajectory Of The Jynneos Market From 2026 To 2030?

    Historical growth stemmed from worldwide campaigns to eliminate smallpox, previous monkeypox outbreaks, the creation of more secure vaccinia platforms, governmental preparedness programs, and public health immunization initiatives.

    The anticipated expansion in the upcoming period stems from factors such as increasing dangers posed by zoonotic diseases, the enlargement of national vaccine stockpiles, greater financial allocation for biodefense, enhanced global disease monitoring systems, and the broadening of adult vaccination campaigns. Concurrently, significant shifts projected for the forecast period encompass a heightened emphasis on preventing novel infectious diseases, the wider application of non-replicating vaccine technologies, the expansion of government-run immunization schemes, increased strategic vaccine reserves, and growing understanding of zoonotic conditions.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20118&type=smp

    Which Factors Are Influencing The Growth Of The Jynneos Market?

    The jynneos market is projected to grow due to the increasing occurrence of monkeypox cases. Monkeypox, a viral illness caused by the monkeypox virus belonging to the orthopoxvirus family, sees a rise in cases attributed to increased global travel and more significant human-wildlife interactions, which facilitate the rapid spread of infectious agents beyond isolated outbreaks. Jynneos is effective against monkeypox as it provides robust viral prevention for at-risk individuals and is considered safer for those with weakened immune systems compared to traditional smallpox vaccines. For example, in September 2024, the European Centre for Disease Prevention and Control, a Europe-based government agency, reported over 100,000 confirmed cases of pox due to monkeypox virus (MPXV) clade I and clade II, including more than 200 deaths, across over 120 countries globally between January 2022 and July 2024. This increase in monkeypox cases is therefore a primary factor driving the expansion of the Jynneos market.

    Jynneos Market Driver: Development Of Combined Vaccines To Enhance Public Health Preparedness

    Key companies within the jynneos market are concentrating on developing combined vaccines to simultaneously target multiple diseases. Combined vaccines are immunizations that offer protection against several illnesses with a single injection, thereby reducing the number of shots needed for complete immunization. For instance, in August 2024, Bavarian Nordic A/S, a Denmark-based biotechnology company, announced that Singapore’s Health Sciences Authority (HSA) had approved JYNNEOS (MVA-BN) for preventing smallpox and pox in adults aged 18 and older who are at high risk for these infections. JYNNEOS (MVA-BN) is a non-replicating vaccine specifically designed to be a safer alternative for individuals, including those who are immunocompromised. Its development aims to bolster public health preparedness and address emerging infectious diseases effectively.

    Which Segment Categories Are Included In The Jynneos Market Segment Analysis?

    The jynneos market covered in this report is segmented –

    1) By Indication: Prevention of Monkeypox, Prevention of Smallpox

    2) By Formulation: Injectable Formulation, Lyophilized Powder for Reconstitution

    3) By Patient Demographics: Adult Patients, Pediatric Patients, High-Risk Populations

    4) By Distribution channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

    5) By End User: Hospitals, Specialty Clinics, Public Health Organizations, Home Healthcare Providers

    Who Are The Active Companies Shaping The Jynneos Market?

    Major companies operating in the jynneos market are Bavarian Nordic A/S

    Get The Full Jynneos Market Report:

    https://www.thebusinessresearchcompany.com/report/jynneos-global-market-report

    Which Region Is The Leading Market For The Jynneos Market?

    North America was the largest region in the jynneos market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the jynneos market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Jynneos Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/jynneos-global-market-report

    Browse Through More Reports Similar to the Global Jynneos Market 2026, By The Business Research Company

    Market Research Services Market Report 2026

    https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

    Data Lake Market Report 2026

    https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

    Varenicline Market Report 2026

    https://www.thebusinessresearchcompany.com/report/varenicline-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Vaccine Contract Manufacturing Market Influenced by Strategic Expansion of Standalone Manufacturing Facilities

    Vaccine Contract Manufacturing Market Influenced by Strategic Expansion of Standalone Manufacturing Facilities

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    How Is The Market Size Of The Vaccine Contract Manufacturing Market Expected To Scale Between 2026 And 2030?

    The vaccine contract manufacturing market has demonstrated strong expansion in recent years. This market is projected to increase from $3.88 billion in 2025 to $4.27 billion in 2026, at a compound annual growth rate (CAGR) of 10.0%. The growth observed in the historic period can be attributed to the broadening of global immunization programs, the escalating complexity of vaccine production processes, an increased reliance on specialized contract manufacturers, the rise of public-private vaccine partnerships, and the establishment of substantial vaccine manufacturing facilities.

    The vaccine contract manufacturing market is projected for substantial expansion in the coming years, reaching a valuation of $6.46 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.9%. This anticipated growth during the forecast period stems from factors such as an escalating need for swift vaccine production scaling, heightened capital allocation towards mRNA and innovative vaccine types, the broadening of commercial manufacturing operations, an increasing emphasis on achieving regional vaccine independence, and the integration of cutting-edge bioprocess technologies. Key trends anticipated within the same forecast timeframe encompass a growing reliance on external providers for vaccine manufacturing, a heightened requirement for adaptable production capacities, the broadening of fill-finish service offerings, an intensifying focus on production adhering to regulatory standards, and a wider embrace of single-use bioprocessing solutions.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12216&type=smp

    Which Drivers Are Supporting The Vaccine Contract Manufacturing Market Growth?

    The global increase in infectious diseases is anticipated to accelerate the expansion of the vaccine contract manufacturing market. These disorders originate from pathogenic microorganisms such as bacteria, viruses, fungi, or parasites. When outbreaks occur, involving conditions like influenza, measles, or new viruses, an urgent requirement for vaccines emerges to prevent wider dissemination. Contract manufacturers are well-positioned to swiftly escalate production in response to these situations. For instance, in October 2024, the World Health Organization, an international public health organization based in Switzerland, reported that approximately 8.2 million people were newly diagnosed with tuberculosis in 2023. This marked an increase from about 7.5 million in 2022, establishing tuberculosis as the leading infectious disease killer. Hence, the growing prevalence of infectious diseases worldwide is a key factor driving the growth of the vaccine contract manufacturing market.

    How Is The Vaccine Contract Manufacturing Market Broken Down By Segment Categories?

    The vaccine contract manufacturing market covered in this report is segmented –

    1) By Service Type: Fill-Finish, Bulk Product

    2) By Vaccine Type: Inactivated Vaccines, Live-Attenuated Vaccines, RNA (Ribonucleic Acid) Vaccines, Subunit Vaccines, Toxoid-Based Vaccines

    3) By Process: Downstream, Upstream

    4) By Scale Of Operation: Preclinical, Clinical, Commercial

    5) By End-Use: Human Use, Veterinary

    Subsegments:

    1) By Fill-Finish: Aseptic Fill-Finish, Lyophilization, Vial Filling, Syringe Filling

    2) By Bulk Product: Cell Culture, Microbial Fermentation, Antigen Production, Buffer Preparation

    Which Trends Are Expected To Impact The Vaccine Contract Manufacturing Market?

    Key companies in the vaccine contract manufacturing market are strategically focusing on establishing new production sites to secure their market presence. The opening of a production site for vaccine contract manufacturing involves setting up a facility specifically designed for the contractual manufacturing and production of vaccines. For example, in September 2023, WuXi Vaccines, a China-based contract development and manufacturing organization (CDMO) specializing in vaccine discovery and production, opened its first dedicated vaccine CDMO facility in Suzhou, China. This expansion signifies a major achievement for the company, bringing about increased capabilities for both drug substance and drug product manufacturing. WuXi Vaccines now delivers an extensive array of services for various vaccines, including process development, drug product development, and the production of clinical-scale drug substances (DS) and small-to-medium sterile drug products (DP). The new standalone site strengthens WuXi Vaccines’ ability to contribute to vaccine development and manufacturing, playing a key role in advancing global healthcare solutions.

    Which Players Are Present In The Vaccine Contract Manufacturing Market Space?

    Major companies operating in the vaccine contract manufacturing market are Pfizer Inc, Johnson & Johnson, AbbVie Inc., Sanofi, GlaxoSmithKline, Merck KGaA, Moderna, BioNTech, GSK Vaccines, AstraZeneca PLC, Ajinomoto Co. Inc., Lonza Group AG, Catalent Inc., Charles River Laboratories International Inc., Serum Institute of India Pvt. Ltd, Samsung Biologics, WuXi Biologics, Novavax, Sinovac Biotech, Emergent BioSolutions Inc., Bio Farma, Hualan Biological Engineering, BioMARC, Bavarian Nordic A/S, AGC Biologics, IDT Biologika GmbH, Bharat Biotech, Goodwin Biotechnology Inc., Biofabri S.L

    Get The Full Vaccine Contract Manufacturing Market Report:

    https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

    Which Geographic Region Dominates The Vaccine Contract Manufacturing Market?

    North America was the largest region in the vaccine contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the vaccine contract manufacturing market report forecast period. The regions covered in the vaccine contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Vaccine Contract Manufacturing Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

    Browse Through More Reports Similar to the Global Vaccine Contract Manufacturing Market 2026, By The Business Research Company

    Antibody Contract Manufacturing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/antibody-contract-manufacturing-global-market-report

    Biopharmaceuticals Contract Manufacturing Market Report

    https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

    Vaccines Market Report

    https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Vaccine Contract Manufacturing Market Developments and Growth Opportunities Across 2026–2030

    Vaccine Contract Manufacturing Market Developments and Growth Opportunities Across 2026–2030

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    How Large Is The Vaccine Contract Manufacturing Market Projected To Become By 2030 Based On Its 2026 Valuation?

    The vaccine contract manufacturing market has experienced robust expansion in recent years. It is forecast to rise from $3.88 billion in 2025 to $4.27 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.0%. The past growth can be attributed to the broadening of global immunization initiatives, the escalating intricacy of vaccine production methods, a greater dependence on specialized contract manufacturers, the proliferation of public-private vaccine partnerships, and the establishment of extensive vaccine production facilities.

    The vaccine contract manufacturing market size is projected to experience substantial expansion over the upcoming years. By 2030, it is anticipated to reach $6.46 billion, exhibiting a compound annual growth rate (CAGR) of 10.9%. This anticipated expansion throughout the projected timeframe stems from factors such as heightened demand for swift vaccine scale-up, increased capital allocation towards mRNA and innovative next-generation vaccines, the broadening of commercial production facilities, a stronger emphasis on achieving regional vaccine autonomy, and the integration of cutting-edge bioprocess technologies. Key developments expected during this period involve a surge in the outsourcing of vaccine manufacturing, an escalating need for adaptable production capabilities, the enhancement of fill-finish service offerings, a sharpened focus on manufacturing processes that comply with regulations, and a greater embrace of single-use bioprocessing systems.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12216&type=smp

    Which Market Drivers Are Supporting The Expansion Of The Vaccine Contract Manufacturing Market?

    The global increase in infectious diseases is projected to stimulate the expansion of the vaccine contract manufacturing market. Infectious diseases are conditions caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites. During outbreaks of these diseases, including influenza, measles, or emerging viruses, there is a pressing requirement for vaccines to prevent further transmission, a need that contract manufacturers can address by quickly scaling up production. For instance, in October 2024, data from the World Health Organization, an international public health organization located in Switzerland, indicated that around 8.2 million people were newly diagnosed with tuberculosis in 2023, an increase from approximately 7.5 million in 2022, establishing tuberculosis as the leading infectious disease fatality. Therefore, the escalating prevalence of infectious diseases worldwide is a key driver for the growth of the vaccine contract manufacturing market.

    What Segment Groups Are Identified Within The Vaccine Contract Manufacturing Market?

    The vaccine contract manufacturing market covered in this report is segmented –

    1) By Service Type: Fill-Finish, Bulk Product

    2) By Vaccine Type: Inactivated Vaccines, Live-Attenuated Vaccines, RNA (Ribonucleic Acid) Vaccines, Subunit Vaccines, Toxoid-Based Vaccines

    3) By Process: Downstream, Upstream

    4) By Scale Of Operation: Preclinical, Clinical, Commercial

    5) By End-Use: Human Use, Veterinary

    Subsegments:

    1) By Fill-Finish: Aseptic Fill-Finish, Lyophilization, Vial Filling, Syringe Filling

    2) By Bulk Product: Cell Culture, Microbial Fermentation, Antigen Production, Buffer Preparation

    What Trends Are Affecting The Expansion Of The Vaccine Contract Manufacturing Market?

    Leading firms within the vaccine contract manufacturing market are prioritizing the establishment of new production sites for vaccine contract manufacturing as a strategy to maintain their competitive standing. A production site opening in vaccine contract manufacturing signifies the creation of a specialized facility dedicated to the contractual manufacturing and production of vaccines. An illustrative example occurred in September 2023 when WuXi Vaccines, a China-based contract development and manufacturing organization (CDMO) specializing in vaccine discovery and production, inaugurated its initial dedicated vaccine CDMO site in Suzhou, China. This expansion represents a significant achievement for the company, enhancing its capacities for both drug substance and drug product manufacturing. WuXi Vaccines now provides a full spectrum of services for various vaccines, encompassing process development, drug product development, and the manufacturing of clinical-scale drug substances (DS) along with small-to-medium sterile drug products (DP). The newly independent site boosts WuXi Vaccines’ ability to contribute to vaccine development and manufacturing, thereby playing a crucial part in advancing worldwide healthcare solutions.

    Which Companies Hold Significant Positions In The Vaccine Contract Manufacturing Market?

    Major companies operating in the vaccine contract manufacturing market are Pfizer Inc, Johnson & Johnson, AbbVie Inc., Sanofi, GlaxoSmithKline, Merck KGaA, Moderna, BioNTech, GSK Vaccines, AstraZeneca PLC, Ajinomoto Co. Inc., Lonza Group AG, Catalent Inc., Charles River Laboratories International Inc., Serum Institute of India Pvt. Ltd, Samsung Biologics, WuXi Biologics, Novavax, Sinovac Biotech, Emergent BioSolutions Inc., Bio Farma, Hualan Biological Engineering, BioMARC, Bavarian Nordic A/S, AGC Biologics, IDT Biologika GmbH, Bharat Biotech, Goodwin Biotechnology Inc., Biofabri S.L

    Read the full vaccine contract manufacturing market report here:

    https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

    How Is The Vaccine Contract Manufacturing Market Distributed Across Key Geographic Regions?

    North America was the largest region in the vaccine contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the vaccine contract manufacturing market report forecast period. The regions covered in the vaccine contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Vaccine Contract Manufacturing Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=12216&type=smp

    Browse Through More Reports Similar to the Global Vaccine Contract Manufacturing Market 2026, By The Business Research Company

    Antibody Contract Manufacturing Global Market Report

    https://www.thebusinessresearchcompany.com/report/antibody-contract-manufacturing-global-market-report

    Biopharmaceuticals Contract Manufacturing Global Market Report

    https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

    Vaccines Global Market Report

    https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Monkeypox cases are accelerating growth in the Jynneos Market 2026

    Monkeypox cases are accelerating growth in the Jynneos Market 2026

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Is The Estimated Market Size Of The Jynneos Market During 2026–2030?

    The historical period’s growth stemmed from worldwide campaigns to eliminate smallpox, previous occurrences of monkeypox, the creation of more secure vaccinia systems, governmental initiatives for readiness, and vaccination drives by public health authorities.

    The anticipated expansion throughout the forecast period stems from factors such as escalating risks of zoonotic diseases, the enlargement of national vaccine stockpiles, increased financial backing for biodefense, enhanced global surveillance mechanisms, and more comprehensive adult immunization initiatives.

    Prominent trends during the forecast period involve a growing emphasis on preventing emerging infectious diseases, the advancement of non-replicating vaccine technologies, an increase in government-led immunization programs, greater accumulation of strategic vaccines, and heightened awareness concerning zoonotic diseases.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20118&type=smp

    Which Major Factors Are Driving The Expansion Of The Jynneos Market?

    The rising prevalence of monkeypox cases is anticipated to stimulate the jynneos market. Monkeypox, a viral ailment caused by the monkeypox virus, belongs to the orthopoxvirus family. The increase in monkeypox cases is driven by heightened global travel and greater human interaction with wildlife, which facilitates the rapid spread of infectious agents, turning isolated outbreaks into wider concerns. Jynneos offers advantages for monkeypox cases by effectively preventing the virus in at-risk individuals and providing a safer alternative for those with weakened immune systems compared to conventional smallpox vaccines. For example, by September 2024, the European Centre for Disease Prevention and Control, a Europe-based government agency, reported over 100,000 confirmed cases of pox from monkeypox virus (MPXV) clade I and clade II, including more than 200 deaths, across over 120 countries globally between January 2022 and July 2024. Consequently, the increasing incidence of monkeypox cases is fueling the expansion of the Jynneos market.

    Jynneos Market Driver: Development Of Combined Vaccines To Enhance Public Health Preparedness

    How Are The Various Segments Of The Jynneos Market Categorized?

    The jynneos market covered in this report is segmented –

    1) By Indication: Prevention of Monkeypox, Prevention of Smallpox

    2) By Formulation: Injectable Formulation, Lyophilized Powder for Reconstitution

    3) By Patient Demographics: Adult Patients, Pediatric Patients, High-Risk Populations

    4) By Distribution channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

    5) By End User: Hospitals, Specialty Clinics, Public Health Organizations, Home Healthcare Providers

    Which Major Firms Influence Developments In The Jynneos Market?

    Major companies operating in the jynneos market are Bavarian Nordic A/S

    Read the full jynneos market report here:

    https://www.thebusinessresearchcompany.com/report/jynneos-global-market-report

    Which Region Currently Holds The Largest Share Of The Jynneos Market?

    North America was the largest region in the jynneos market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the jynneos market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Jynneos Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=20118&type=smp

    Browse Through More Reports Similar to the Global Jynneos Market 2026, By The Business Research Company

    Market Research Services Market Report 2026

    https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

    Data Lake Market Report 2026

    https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

    Varenicline Market Report 2026

    https://www.thebusinessresearchcompany.com/report/varenicline-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Monkeypox cases are accelerating growth in the Jynneos Market 2026

    Monkeypox cases are accelerating growth in the Jynneos Market 2026

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Is The Estimated Market Size Of The Jynneos Market During 2026–2030?

    The historical period’s growth stemmed from worldwide campaigns to eliminate smallpox, previous occurrences of monkeypox, the creation of more secure vaccinia systems, governmental initiatives for readiness, and vaccination drives by public health authorities.

    The anticipated expansion throughout the forecast period stems from factors such as escalating risks of zoonotic diseases, the enlargement of national vaccine stockpiles, increased financial backing for biodefense, enhanced global surveillance mechanisms, and more comprehensive adult immunization initiatives.

    Prominent trends during the forecast period involve a growing emphasis on preventing emerging infectious diseases, the advancement of non-replicating vaccine technologies, an increase in government-led immunization programs, greater accumulation of strategic vaccines, and heightened awareness concerning zoonotic diseases.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20118&type=smp

    Which Major Factors Are Driving The Expansion Of The Jynneos Market?

    The rising prevalence of monkeypox cases is anticipated to stimulate the jynneos market. Monkeypox, a viral ailment caused by the monkeypox virus, belongs to the orthopoxvirus family. The increase in monkeypox cases is driven by heightened global travel and greater human interaction with wildlife, which facilitates the rapid spread of infectious agents, turning isolated outbreaks into wider concerns. Jynneos offers advantages for monkeypox cases by effectively preventing the virus in at-risk individuals and providing a safer alternative for those with weakened immune systems compared to conventional smallpox vaccines. For example, by September 2024, the European Centre for Disease Prevention and Control, a Europe-based government agency, reported over 100,000 confirmed cases of pox from monkeypox virus (MPXV) clade I and clade II, including more than 200 deaths, across over 120 countries globally between January 2022 and July 2024. Consequently, the increasing incidence of monkeypox cases is fueling the expansion of the Jynneos market.

    Jynneos Market Driver: Development Of Combined Vaccines To Enhance Public Health Preparedness

    How Are The Various Segments Of The Jynneos Market Categorized?

    The jynneos market covered in this report is segmented –

    1) By Indication: Prevention of Monkeypox, Prevention of Smallpox

    2) By Formulation: Injectable Formulation, Lyophilized Powder for Reconstitution

    3) By Patient Demographics: Adult Patients, Pediatric Patients, High-Risk Populations

    4) By Distribution channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

    5) By End User: Hospitals, Specialty Clinics, Public Health Organizations, Home Healthcare Providers

    Which Major Firms Influence Developments In The Jynneos Market?

    Major companies operating in the jynneos market are Bavarian Nordic A/S

    Read the full jynneos market report here:

    https://www.thebusinessresearchcompany.com/report/jynneos-global-market-report

    Which Region Currently Holds The Largest Share Of The Jynneos Market?

    North America was the largest region in the jynneos market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the jynneos market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Jynneos Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=20118&type=smp

    Browse Through More Reports Similar to the Global Jynneos Market 2026, By The Business Research Company

    Market Research Services Market Report 2026

    https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

    Data Lake Market Report 2026

    https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

    Varenicline Market Report 2026

    https://www.thebusinessresearchcompany.com/report/varenicline-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Jynneos Market Report 2026–2035: Key Forecasts and Growth Areas

    Global Jynneos Market Report 2026–2035: Key Forecasts and Growth Areas

    Uncover key drivers, emerging technologies, and competitive movements shaping the jynneos market from 2026–2035 with trusted insights from The Business Research Company

    How is the Jynneos Market size predicted to change over the forecast window of 2026–2035?

    Historical growth can be ascribed to a combination of factors, including worldwide smallpox eradication endeavors, previous monkeypox occurrences, the creation of more secure vaccinia platforms, governmental readiness initiatives, and public health immunization drives.

    The expansion anticipated in the upcoming period is attributable to several factors, including the increasing risks associated with zoonotic diseases, the enlargement of national vaccine reserves, a rise in financial support for biodefense, enhancements in global surveillance systems, and the broadening reach of adult immunization programs.

    Significant trends projected for the forecast timeframe involve an escalating emphasis on preventing emerging infectious diseases, the proliferation of non-replicating vaccine technologies, an increase in government-led immunization initiatives, the accumulation of strategic vaccines, and a growing understanding of zoonotic ailments.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20118&type=smp

    Which Drivers Are Contributing To The Expansion Of The Jynneos Market?

    The rising incidence of monkeypox cases is projected to stimulate growth in the jynneos market. Monkeypox, a viral illness caused by the monkeypox virus within the orthopoxvirus family, is experiencing an increase in cases primarily due to heightened global travel and greater human-wildlife interaction, which facilitates the rapid spread of infectious agents beyond isolated outbreaks. Jynneos offers a significant advantage for monkeypox prevention because it effectively protects at-risk individuals and presents a safer option for those with compromised immune systems compared to conventional smallpox vaccines. For example, data from the European Centre for Disease Prevention and Control, a Europe-based government agency, indicated that between January 2022 and July 2024, over 100,000 confirmed cases of pox caused by monkeypox virus (MPXV) clade I and clade II, including over 200 deaths, were reported by more than 120 countries globally, highlighting the escalating public health concern. Consequently, the increasing number of monkeypox infections is a primary catalyst driving the expansion of the Jynneos market. This market expansion is further advanced by the development of combined vaccines aimed at enhancing public health preparedness, a central focus for companies operating in the jynneos market. Combined vaccines are immunizations that protect against multiple diseases with a single shot, thereby reducing the number of injections needed for full immunity. A notable example occurred in August 2024, when Bavarian Nordic A/S, a Denmark-based biotechnology company, announced that Singapore’s Health Sciences Authority (HSA) had approved JYNNEOS (MVA-BN) for the prevention of smallpox and pox in adults aged 18 and older considered at high risk for these infections. JYNNEOS (MVA-BN) is designed as a non-replicating vaccine to provide a safer alternative, particularly for immunocompromised individuals, and was developed with the objective of improving public health readiness and addressing emerging infectious diseases.

    What Segment Categories Are Covered In The Jynneos Market?

    The jynneos market covered in this report is segmented –

    1) By Indication: Prevention of Monkeypox, Prevention of Smallpox

    2) By Formulation: Injectable Formulation, Lyophilized Powder for Reconstitution

    3) By Patient Demographics: Adult Patients, Pediatric Patients, High-Risk Populations

    4) By Distribution channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

    5) By End User: Hospitals, Specialty Clinics, Public Health Organizations, Home Healthcare Providers

    Which Major Industry Participants Are Leading The Jynneos Market Growth?

    Major companies operating in the jynneos market are Bavarian Nordic A/S

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/jynneos-global-market-report

    Which Region Is Expected To Experience The Fastest Growth In The Jynneos Market?

    North America was the largest region in the jynneos market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the jynneos market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Jynneos Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=20118&type=smp

    Browse Through More Reports Similar to the Global Jynneos Market 2026, By The Business Research Company

    Market Research Services Market Report 2026

    https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

    Data Lake Market Report 2026

    https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

    Varenicline Market Report 2026

    https://www.thebusinessresearchcompany.com/report/varenicline-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model